{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:46Z","timestamp":1792093786241,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00059-025-05362-6","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T10:45:22Z","timestamp":1768301122000},"page":"362-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic significance of H2FPEF and HFA-PEFF scores with oncostatin\u00a0M levels in heart failure with preserved ejection fraction","Diagnostische Bedeutung des H2FPEF- und des HFA-PEFF-Scores unter Ber\u00fccksichtigung der Oncostatin-M-Werte bei Herzinsuffizienz mit erhaltener Ejektionsfraktion"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9405-9593","authenticated-orcid":false,"given":"Hasan","family":"Sari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1294-352X","authenticated-orcid":false,"given":"Oznur","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-2180","authenticated-orcid":false,"given":"Yakup","family":"Alsancak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"3","key":"5362_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMOA052256\/ASSET\/E1DA1335-289A-483D-B79B-BCA93A28764C\/ASSETS\/IMAGES\/LARGE\/NEJMOA052256_T2.JPG","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan\u00a0TE, Hodge\u00a0DO, Herges\u00a0RM, Jacobsen\u00a0SJ, Roger\u00a0VL, Redfield\u00a0MM (2006) Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine 355(3):251\u2013259. https:\/\/doi.org\/10.1056\/NEJMOA052256\/ASSET\/E1DA1335-289A-483D-B79B-BCA93A28764C\/ASSETS\/IMAGES\/LARGE\/NEJMOA052256_T2.JPG","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"5362_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/EJHF.483","volume":"18","author":"EES Van Riet","year":"2016","unstructured":"Van Riet\u00a0EES, Hoes\u00a0AW, Wagenaar\u00a0KP, Limburg\u00a0A, Landman\u00a0MAJ, Rutten\u00a0FH (2016) Epidemiology of heart failure: The prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 18(3):242\u2013252. https:\/\/doi.org\/10.1002\/EJHF.483","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"5362_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/S41569-020-0363-2","volume":"17","author":"BA Borlaug","year":"2020","unstructured":"Borlaug\u00a0BA (2020) Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 17(9):559\u2013573. https:\/\/doi.org\/10.1038\/S41569-020-0363-2","journal-title":"Nat Rev Cardiol"},{"issue":"40","key":"5362_CR4","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/EURHEARTJ\/EHZ641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske\u00a0B, Tsch\u00f6pe\u00a0C, De Boer\u00a0RA et\u00a0al (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart\u00a0J 40(40):3297\u20133317. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHZ641","journal-title":"Eur Heart J"},{"issue":"9","key":"5362_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","volume":"138","author":"YNV Reddy","year":"2018","unstructured":"Reddy\u00a0YNV, Carter\u00a0RE, Obokata\u00a0M, Redfield\u00a0MM, Borlaug\u00a0BA (2018) A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 138(9):861\u2013870. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034646","journal-title":"Circulation"},{"key":"5362_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/S10254-003-0013-1","volume":"149","author":"M Tanaka","year":"2003","unstructured":"Tanaka\u00a0M, Miyajima\u00a0A (2003) Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 149:39\u201352. https:\/\/doi.org\/10.1007\/S10254-003-0013-1","journal-title":"Rev Physiol Biochem Pharmacol"},{"issue":"5","key":"5362_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/J.STEM.2011.08.013","volume":"9","author":"T Kubin","year":"2011","unstructured":"Kubin\u00a0T, P\u00f6ling\u00a0J, Kostin\u00a0S et\u00a0al (2011) Oncostatin M Is a Major Mediator of Cardiomyocyte Dedifferentiation and Remodeling. Cell Stem Cell 9(5):420\u2013432. https:\/\/doi.org\/10.1016\/J.STEM.2011.08.013","journal-title":"Cell Stem Cell"},{"issue":"1","key":"5362_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-10859-w","volume":"10","author":"H Abe","year":"2019","unstructured":"Abe\u00a0H, Takeda\u00a0N, Isagawa\u00a0T et\u00a0al (2019) Macrophage hypoxia signaling regulates cardiac fibrosis via Oncostatin M. Nature Communications 10(1):1\u201310. https:\/\/doi.org\/10.1038\/s41467-019-10859-w","journal-title":"Nature Communications"},{"issue":"4","key":"5362_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.5937\/JOMB0-37150","volume":"41","author":"AM Gusakova","year":"2022","unstructured":"Gusakova\u00a0AM, Suslova\u00a0TE, Kercheva\u00a0MA, Kologrivova\u00a0IV, Ryabova\u00a0TR, Ryabov\u00a0VV (2022) Association of increased oncostatin M with adverse left ventricular remodeling in patients with myocardial infarction. J\u00a0Med Biochem 41(4):441\u2013441. https:\/\/doi.org\/10.5937\/JOMB0-37150","journal-title":"J Med Biochem"},{"issue":"3","key":"5362_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2217\/FCA-2016-0063","volume":"13","author":"D Gruson","year":"2017","unstructured":"Gruson\u00a0D, Ferracin\u00a0B, Ahn\u00a0SA, Rousseau\u00a0MF (2017) Elevation of plasma oncostatin M in heart failure. Future Cardiol 13(3):219\u2013227. https:\/\/doi.org\/10.2217\/FCA-2016-0063","journal-title":"Future Cardiol"},{"issue":"1","key":"5362_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/INTERCARDIOPERS.2025.2025-2-3","volume":"1","author":"L A\u015fk\u0131n","year":"2025","unstructured":"A\u015fk\u0131n\u00a0L, Tanr\u0131verdi\u00a0O, Bar\u0131\u015f\u00a0V, A\u015fk\u0131n\u00a0L, Tanr\u0131verdi\u00a0O, Bar\u0131\u015f\u00a0V (2025) Oncostatin M and Cardiovascular Diseases: A\u00a0Narrative Review. Interventional Cardiology Perspectives 1(1):1\u20135. https:\/\/doi.org\/10.4274\/INTERCARDIOPERS.2025.2025-2-3","journal-title":"Interventional Cardiology Perspectives"},{"issue":"10","key":"5362_CR12","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/EJHF.890","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel\u00a0O, Mebazaa\u00a0A, Harjola\u00a0VP et\u00a0al (2017) Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19(10):1242\u20131254. https:\/\/doi.org\/10.1002\/EJHF.890","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"5362_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/J.JCHF.2018.05.018\/SUPPL_FILE\/MMC1.DOCX","volume":"6","author":"N Savji","year":"2018","unstructured":"Savji\u00a0N, Meijers\u00a0WC, Bartz\u00a0TM et\u00a0al (2018) The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. JACC Heart Fail 6(8):701\u2013709. https:\/\/doi.org\/10.1016\/J.JCHF.2018.05.018\/SUPPL_FILE\/MMC1.DOCX","journal-title":"JACC Heart Fail"},{"issue":"4","key":"5362_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus\u00a0WJ, Tsch\u00f6pe\u00a0C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J\u00a0Am Coll Cardiol 62(4):263\u2013271. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"5362_CR15","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/EURHEARTJ\/EHAB368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB368","journal-title":"Eur Heart J"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-025-05362-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-025-05362-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-025-05362-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:28:51Z","timestamp":1792092531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-025-05362-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5362"],"URL":"https:\/\/doi.org\/10.1007\/s00059-025-05362-6","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.\u00a0Sari, O.\u00a0Keskin and Y.\u00a0Alsancak declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}